GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Interest Expense

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Interest Expense : NT$-0.09 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Great Novel Therapeutics Biotech & Medicals's interest expense for the six months ended in Dec. 2023 was NT$ -0.08 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-0.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Great Novel Therapeutics Biotech & Medicals's Operating Income for the six months ended in Dec. 2023 was NT$ -30.21 Mil. Great Novel Therapeutics Biotech & Medicals's Interest Expense for the six months ended in Dec. 2023 was NT$ -0.08 Mil. Great Novel Therapeutics Biotech & Medicals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Great Novel Therapeutics Biotech & Medicals Interest Expense Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Interest Expense Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial - -0.02 - - -0.09

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 0.01 -0.01 -0.08

Great Novel Therapeutics Biotech & Medicals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Great Novel Therapeutics Biotech & Medicals's Interest Expense for the six months ended in Dec. 2023 was NT$-0.08 Mil. Its Operating Income for the six months ended in Dec. 2023 was NT$-30.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was NT$10.88 Mil.

Great Novel Therapeutics Biotech & Medicals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Great Novel Therapeutics Biotech & Medicals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Interest Expense
Comparable Companies
TPE:1733 ROCO:4194 ROCO:4724 ROCO:6564 ROCO:4130 ROCO:6580 ROCO:4168 ROCO:4911 ROCO:6879 ROCO:6926 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Website
http://www.gntbm.com.tw
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines